NeuBase Therapeutics (STU:O7P) ROCE % : -48.65% (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NeuBase Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2023 was -48.65%.

NeuBase Therapeutics ROCE % Historical Data

The historical data trend for NeuBase Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics ROCE % Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

ROCE %

Get a 7-Day Free Trial

-96.36

-79.91

-508.58

-82.71

-55.63

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-98.35	-64.74	-75.71	-76.62	-48.65

NeuBase Therapeutics ROCE % Calculation

NeuBase Therapeutics's annualized ROCE % for the fiscal year that ended in Sep. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2021 )		(A: Sep. 2020 )		(A: Sep. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2021 )		(A: Sep. 2020 )		(A: Sep. 2021 )
	=	-21.57	/	( ( (29.243 - 2.674)	+	(54.543 - 3.565) )	/ 2 )
	=	-21.57	/	( (26.569	+	50.978)	/ 2 )
	=	-21.57	/	38.7735
	=	-55.63 %

NeuBase Therapeutics's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-6.824	/	( ( (20.614 - 5.652)	+	(17.448 - 4.357) )	/ 2 )
	=	-6.824	/	( ( 14.962	+	13.091 )	/ 2 )
	=	-6.824	/	14.0265
	=	-48.65 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

NeuBase Therapeutics (STU:O7P) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NeuBase Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (STU:O7P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NBSE:USA O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines